Prominent Scientist Julio Aguirre-Ghiso, Ph.D., To Lead New Cancer Dormancy and Tumor Microenvironment Institute at Albert Einstein Cancer Center

Albert Einstein Cancer Center (AECC), Albert Einstein College of Medicine, and Montefiore Health System today announced that leading cancer biologist Julio Aguirre-Ghiso, Ph.D., has been named founding director of the Cancer Dormancy and Tumor Microenvironment Institute (CDTMI), director of the Gruss-Lipper Biophotonics Center, and co-leader of the AECC Tumor Microenvironment and Metastasis Program. He will also be an endowed professor of cell biology at Einstein. He will assume his new roles on October 1, 2021.

Hormone Drugs May Disarm COVID-19 Spike Protein and Stop Disease Progression

Hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease, suggests a new preclinical study from researchers in the Abramson Cancer Center at the University of Pennsylvania and published online in Cell Press’s iScience.

New nanotechology design provides hope for personalized vaccination for treating cancer

A new study demonstrates the use of charged nanoscale metal-organic frameworks for generating free radicals using X-rays within tumor tissue to kill cancer cells. The same frameworks can be used for delivering immune signaling molecules to activate the immune response against tumor cells.

HDAC6 Can Control Tumor Growth and Halt Metastasis in Triple-Negative Breast Cancer

Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published in the journal Cancer Research by investigators at the GW Cancer Center.